Avidian Wealth Solutions LLC Buys 75 Shares of Zoetis Inc. (NYSE:ZTS)

Avidian Wealth Solutions LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 4.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,914 shares of the company’s stock after acquiring an additional 75 shares during the period. Avidian Wealth Solutions LLC’s holdings in Zoetis were worth $378,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Blue Bell Private Wealth Management LLC lifted its stake in Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the last quarter. Independence Bank of Kentucky lifted its position in shares of Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares during the last quarter. Ramirez Asset Management Inc. bought a new position in shares of Zoetis during the 3rd quarter worth $35,000. First Financial Corp IN increased its holdings in Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after acquiring an additional 79 shares during the last quarter. Finally, Bogart Wealth LLC raised its stake in Zoetis by 188.9% in the 3rd quarter. Bogart Wealth LLC now owns 260 shares of the company’s stock valued at $45,000 after acquiring an additional 170 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. Barclays reduced their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group dropped their target price on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $212.38.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,209 shares of company stock valued at $371,293 in the last quarter. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of ZTS stock traded down $1.83 on Monday, reaching $165.24. The company’s stock had a trading volume of 1,481,050 shares, compared to its average volume of 3,157,763. The company has a market capitalization of $75.40 billion, a P/E ratio of 32.12, a PEG ratio of 2.62 and a beta of 0.86. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The stock’s 50 day simple moving average is $168.88 and its 200-day simple moving average is $178.93. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter last year, the firm posted $1.31 EPS. The company’s revenue was up 9.5% compared to the same quarter last year. As a group, equities analysts predict that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.05%. Zoetis’s dividend payout ratio is presently 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.